Therapeutic Glaucoma

>

Latest News

PolyActiva secures $40 million AUD in Series C funding
PolyActiva secures $40 million AUD in Series C funding

June 14th 2025

Funding will support the continued clinical advancement of its lead ocular implant candidate, PA5108, for the reduction of IOP in patients with ocular hypertension and glaucoma.

(Image credit: AdobeStock/RFBSIP) The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma
The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma

June 4th 2025

Nicox releases results from Whistler phase 3b trial in IOP-lowering eye drops
Nicox releases results from Whistler phase 3b trial in IOP-lowering eye drops

May 15th 2025

 Santen receives marketing authorization application approval from NMPA of China for tafluprost/timolol maleate (Tapcom) in patients with open-angle glaucoma
Santen receives marketing authorization application approval from NMPA of China for tafluprost/timolol maleate (Tapcom) in patients with open-angle glaucoma

April 7th 2025

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial
Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial

March 24th 2025

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.